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ABSTRACT 
The formulation of oral disintegrating films has led to the development of wafers which has modified itself in the recent past years. Wafers are more 
advantageous over other conventional dosage forms as well as from other oral disintegrating solid dosage forms. The major difficulty in formulating 
wafers is the choice of drugs to be incorporated. Wafers with low dose of active pharmaceutical ingredient (API) and with a good mouth feel are 
prepared for making it more patients compliant. The manufacturing procedures are quite similar to oral disintegrating film but the composition of 
polymers may vary. The wafers requires expensive packaging and care should be taken while handling, storage & transport. In spite of these 
hardships, wafers have become popular between geriatric and paediatric population because of its ease of administration and bioavailability. 
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INTRODUCTION 
In the recent few decades, prioritise has been focused for more patient-
compliant dosage forms. Oral transmucosal route for drug delivery is 
preferred over other routes because of its versatility. The conventional 
pharmaceutical dosage forms are incapable of controlling the rate of 
drug delivery; over which novel drug delivery system maintain the drug 
concentration in the therapeutic range for a longer period of time. The 
basic rationale for controlled drug delivery is to alter the 
pharmacokinetics and pharmacodynamics of pharmacologically active 
substances either by using novel drug delivery system or by modification 
of its molecular structure and physiological parameters and incorporate 
it in a convenient route of administration [1]. 
Fast-dissolving drug delivery system was first developed in the late 
1970s which is an alternative to after dosage forms, for podiatric 
and geriatric patients who experience difficulties in swallowing 
traditional oral solid dosage forms [2]. 
Oral fast-dissolving dosage forms 
It is a solid dosage form that disperses or disintegrates quickly in the 
oral cavity, resulting in solution/suspension without the need for the 
administration of water [3]. 
Advantages of oral fast dissolving dosage forms [4-5] 
• It controls the release rate of drug, thus decreases toxicity and 
adverse drug reaction.  
• It optimizes the utilization of a smaller drug dose to produce the 
same therapeutic effect as a larger dose in other dosage forms. 
• It releases the drug at their site of action. 
• It protects the drug from first pass metabolism and improves 
dissolution. 
• It dissolves in short duration of time when placed in mouth 
without drinking water or chewing.  
Classification of fast dissolving technology [6] 
• Lyophilized system  
• Compressed tablet based system 
• Oral thin films/strips 
Oral thin films/strips 
These are the most convenient and advance form of oral solid 
dosage form due to the efficiency of dissolving within minutes in the 
oral cavity when it comes in contact of saliva. It neither requires 
chewing nor water for administration. It gives quick absorption and 
instant bioavailability of drugs due to the high blood flow and 
permeability of oral mucosa [7]. 
Oral wafers/oro-dispersible wafer strips 
These are paper thin polymer films of typically 2-8 cm2 area and 20-
500 µm thickness, containing typically less than 50 mg of API. They 
are administered directly on the tongue [8]. 
Classification of oral wafers [9, 10] 
A. Flash release wafers 
• Area–2-8 cm2. 
• Thickness–20-70 µm. 
• Dissolution–60 s maximum. 
• Single layered structure. 
• Soluble excipients are used. 
• Highly hydrophilic polymers are required. 
• Drugs are dispersed in solid solution phase. 
• It is applied to the upper palate of the tongue. 
B. Mucoadhesive melt-away wafers 
• Area–2-7 cm2. 
• Thickness–50-500 µm. 
• Dissolution–1-3 min. 
• Single or multi-layered structure. 
• Soluble excipients are used. 
• Hydrophilic polymers are required. 
• Drugs are dispersed in solid solution or suspension. 
• It is applied to gingival or buccal region. 
C. Mucoadhesive sustained release wafers 
• Area–2-4 cm2. 
• Thickness–50-250 µm. 
• Dissolution–8-10 h. 
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• Multi-layered structure. 
• Excipients with low solubility are used. 
• Non-soluble polymers are used. 
• Drugs are dispersed in solid solution or suspension. 
• It is applied to the gingival or oral cavity. 
Positive aspects of wafers as oral fast dissolving films [11] 
• Attractive dosage form with new active ingredients. 
• Improvement of established products. 
• Access to a new indication by means of a new absorption profile 
even for existing active ingredients. 
• Optimization of bioavailability. 
• Innovative technology for the product. 
• The increase of product appeals through the innovative format. 
• Exclusivity and cutting edge technology position in the market 
through a step forward. 
• No first pass effect. 
• Controlled release. 
• Improved bioavailability, translates to lower doses. 
• Reduction of side-effects. 
• Reduced impact on the gastrointestinal tract. 
• Discrete and easy application. 
• Excellent compliance, especially for geriatric and paediatric patients. 
• Good mouthfeel and stability. 
Drawbacks of wafers 
• A high dose cannot be incorporated, but concentration level of 
active ingredients can be improved up to 50% per dose weight. 
• Expensive packaging is required. 
• Excessive bitter drugs are not feasible. 
• Handling concerns during manufacturing. 
• Drugs which are unstable at oral pH cannot be incorporated. 
• Drugs which irritate mucosa cannot be administered. 
Mechanism of action of wafers 
Wafers are placed on a patient’s tongue or any oral mucosal tissue. 
They are instantly wet by saliva due to the presence of hydrophilic 
polymer and other excipients; the film rapidly hydrates and 
dissolves to release the medication for mucosal absorption. [10] 
Anatomical and physiochemical of oral mucosal cavity [11-16] 
 
 
Fig. 1: Mucosal region of mouth 
 
The oral mucosa is composed of an outermost layer of stratified 
squamous epithelium. Below this lies a basement membrane, a 
lamina propria followed by the sub-mucosa as the innermost layer. 
The buccal mucosal site offers a smooth, immobile surface with 
vascular perfusion, in contrast to the sublingual mucosal site, which 
lacks an immobile mucosal surface. When compared to other 
mucosal areas, the buccal mucosa is more tolerant to potential 
allergens, with less impact for irreversible damage and relatively 
lower enzymatic activity. 
Drug absorption through the buccal cavity can take place either by 
the transcellular route (intercellular route) or paracellular pathway. 
The oral mucosa is in general intermediate between that of the 
epidermis and intestinal mucosa in terms of permeability. The wafer 
quickly dissolves in the oral cavity, and the active moiety absorbs via 
oral mucosa into the blood stream. 
Objective of formulating wafers 
• To improve patient compliance and provide rapid onset of action 
• To reduce the extent of hepatic first pass metabolism. 
• To reduce side effects associated with the API by reducing the 
dose. 
• To enhance oral bioavailability of molecules. 
Some companies like Labtec Pharma, Pfizer, Novartis, Del, Zydis, etc 
are producing wafer as a dosage form [4]. 
Formulation of wafers [18-20] 
A. Drug or active pharmaceutical ingredient 
Generally, 5-30% of API can be incorporated in the buccal film. 
Water soluble APIs are present in the dissolved state in the buccal 
film/solid solution form. Micro ionized API will improve the texture 
of the film and also for better dissolution and uniformity in the 
buccal film [21]. 
The ideal characteristics of a drug to be selected: [22] 
• The drug should have a pleasant taste. 
• The incorporated drug should have a low dose. 
• Possess smaller and moderate molecular weight. 
• Good stability and solubility in water as well as saliva. 
• Partially unionizes at the pH of the oral cavity. 
• Ability to permeate oral mucosal tissues. 
• BCS class-I drugs are used. 
Various methods for improving the palatability of the 
formulation [5] 
a. Simplest method 
It includes the blending of bitter drugs with pleasant taste drugs, 
called as obscuration technique. 
b. Barrier method 
To mask bitter taste by complexation, polymeric coating, 
micronisationetc. 
B. Wafer forming polymers 
The polymers form the majority of formulation i.e. they are used 
45% (w/w), alone or in combination to obtain the desired 
properties. The wafer should be tough enough so that there won’t be 
any damage while handling or during transportation used in alone 
or in combination to improve hydrophilicity [23, 24]. Some 
examples of polymers are methyl cellulose, pullulan, gelatin, gum 
acacia, tragacanth, etc. 
Ideal properties of the wafer forming polymers [25, 26] 
• Non-toxic, non-irritant and devoid of leachable impurities. 
• Good wetting and good shelf-life. 
• Pleasant mouth feel. 
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• Devoid of secondary infections in the oral mucosa or dental regions. 
• Local enzyme inhibition action along with penetration 
enhancing the property. 
C. Plasticizers 
Plasticizers used should be compatible with the polymer and also with 
the type of solvent employed. It is added up to 20% (w/w) of the 
formulation. It improves the flexibility of the strip and reduces the 
brittleness. It reduces the glass transition temperature of the polymer 
used in the range of 40-60 degree Celsius for the non-aqueous solvent 
system and below 75 °C for the aqueous system [28]. However, 
inappropriate use of plasticizers may lead to cracking, splitting and 
peeling of wafers. It is also reported that the use of certain 
plasticizers may also affect the absorption rate of the drug [29]. The 
commonly used plasticizers are glycerol, dibutyl phthalate, 
polyethylene glycols, etc. 
D. Saliva stimulating agent 
The saliva stimulating agents are the excipients that increase the saliva 
production rate, aids in the faster disintegration of wafer when used in a 
concentration of 2-6% (w/w). The stimulation of salivation can be 
measured by comparing the amount of resting flow and stimulated flow 
at the equal time under the same condition. The stimulant action of 
sweeteners depends on the sweetness value. Sweeteners used as saliva 
stimulating agents are fructose, xylose, maltose, lactose, and glucose. 
Certain flavouring agents are also used like peppermint, cinnamon, 
nutmeg, vanilla, cocoa, coffee, chocolate, apple, cherry, etc [30-33]. 
E. Surfactant 
It acts as solubilizing, wetting and dispersing agents in the 
formulation so that the wafer gets dissolved within seconds and 
release active agent quickly. Some of the commonly used surfactants 
are sodium lauryl sulphate, benzalkonium chloride, benzethonium 
chloride, etc [34]. 
F. Sweetening agents 
Sweeteners play an important role in improving compliance wafers 
in the paediatric population. Natural sweeteners and artificial 
sweeteners play an important role in improving the palatability of 
oral dissolving formulations. The uses of natural sweeteners are 
restricted in people with diabetics, and thus, artificial sweeteners 
are used. The classical source of sweetness is sucrose which is 
derived from cane or beet in the form of liquid or dry state; dextrose, 
fructose, glucose and maltose are also used. Saccharine, cyclamate, 
and aspartame are the first generations of artificial sweeteners 
followed by acesulfame-K, sucralose, alitame and neotame which fall 
under the second generation artificial sweeteners. All of the artificial 
sweeteners have toxic and carcinogenic effects, so natural 
sweeteners like rebiana is used [35]. 
G. Flavouring agents 
Perception of flavours changes according to individual’s ethnicity 
and liking. The acceptance of the oral disintegrating or dissolving 
formulation by an individual by and large depends on the initial 
flavour quality which is observed in first few seconds after the 
product has been consumed and the after taste of the formulation 
which tastes for at least about 10 min. Flavours can be used alone or 
in combination. The amount of flavour needed to mask the taste 
depends on the flavour type and its strength. Flavouring agents can 
be selected from synthetic flavour oils, oleo resins and extract 
derived from various plants. Various flavour oils added are 
peppermint oil, cinnamon oil, spearmint oil, oil of nutmeg, etc [36]. 
H. Colouring agents 
Pigments or FD&C approved colouring agents are incorporated like 
titanium dioxide. EU colours, natural colour, and custom Pantone-
matched colour are also used [37]. 
I. Cooling agent 
Cooling agents are added to give mouth-feel effect and to enhance 
the flavour like WS3, WS23, Utracoll-II can be used [38]. 
J. Thickening agent 
It improves the viscosity and consistency of dispersion or solution before 
casting of wafers. Agents like gum, carrageenan and cellulosic derivatives 
in the concentration of 5% (w/w) are used as thickening agents [9]. 
K. Penetration enhancers 
These are required for a drug to reach the systemic circulation to 
exert its action. These must be non-irritant. The most common 
classes of buccal penetration enhancers include fatty acid, bile salt, 
azone, alcohols, chitosan and its derivatives [39-41]. 
L. Taste masking agents 
Examples of taste masking agents are sorbitol, mannitol, xyliol, dextrose, 
etc [42]. The various approaches for taste masking of bitter drugs:  
• Polymer coating solution of drug or its suspension applied to a 
substrate. 
• Particles or entities of active drugs are coated directly. 
• Granulation with compatible excipients followed by polymer 
coating. 
Manufacturing methodologies of wafer 
Various approaches to the manufacturing of rapid dissolving wafers 
are classified as follows: [43]. 
A. Casting and drying—(a) solvent casting (b) semi-solid casting 
B. Extrusion—(a) hot-melt extrusion (b) solid dispersion extrusion 
C. Freeze dried wafers 
D. Rolling method 
Solvent casting method 
This technique is employed to manufacture fast dissolving wafers of 
size 3x2 cm2 and 2x2 cm2. Water soluble polymers are dissolved in 
the aqueous vehicle. The drug along with other excipients is dissolved 
in suitable solvent, and both are mixed and stirred. It is finally casted 
on Petri dish or plate made up of glass, plastic or Teflon and dried. 
Specific types of equipment are used at large scale production as well 
as rollers are used for pouring the solution on an inert base. Entrapped 
air is removed by vacuum. The final step is drying the wafer, removes 
the solvent and helps to obtain the finished product. Wafers are dried 
after which cutting, stripping and packaging is done [44-45]. 
Advantages 
• Better uniformity of thickness and better clarity than extrusion. 
• Wafer has fine gloss and freedom from defects such as die lines. 
• Wafer has more flexibility and better physical properties. 
Disadvantages 
• The polymer used must be soluble in volatile solvent or water. 
• Stable solution with a reasonable minimum solid content and 
viscosity should be formed. 
• Multiple casting techniques may be selected on the basis of the 
fluid rheology, desired applied mass and required dosage 
uniformity. 
• Formation of a homogeneous and release from the casting 
support must be possible. 
 
Fig. 2: solvent casting system 
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Semi-solid casting method 
This technique is employed to manufacture flash release wafers of 
size 0.015-0.05 inch. A solution of water soluble wafer forming 
polymer is prepared. Then the solution is further added to acid 
insoluble polymer solution i.e. either cellulose acetate phthalate or 
cellulose acetate butyrate in sodium or ammonium hydroxide 
solution in the ratio 1:4. Then plasticizers are added to obtain a gel 
mass which is casted to wafers using heat controlled drums [46]. 
Solid dispersion extrusion 
The immiscible components are extruded with drug, and then solid 
dispersions are prepared. Solid dispersions are shaped in wafers by 
use of dies [47]. 
Advantages 
• Fewer processing steps. 
• More uniform dispersion of the fine particles because of intense 
mixing and agitation. 
Hot-melt extrusion 
The active moiety and other ingredients are mixed in a dry state, 
subjected to the heating process and then extruded out in a molten 
state. The solvent is completely eliminated. The strips are further 
cooled and cut to the desired sixe. The high temperature used in this 
process may degrade thermolabile APIs [48-50]. 
Advantages 
• No need to use solvent or water. 
• Fewer processing steps. 
• Compressibility properties of the API may not be of importance. 
• Good dispersion mechanism & bioavailability for poorly soluble 
drugs. 
• More uniform dispersion of the fine particles because of less 
intense mixing and agitation. 
• Less energy compared with high shear methods. 
• Cost effective process with less processed time and unit operations. 
Disadvantages 
• Thermal degradation due to high temperature. 
• Lower melting point binder risks a situation where 
melting/softening of the binder occurs during handling and 
storage of agglomerates. 
• Higher melting point binders require high melting temperature and 
can contribute to volatility problems especially for heat labile 
materials. 
• Flow properties of the polymers are essential to processing. 
 
Fig. 3: Extrusion method 
 
Freeze-dried wafers 
A polymer of concentration 1% (w/w) and lactose as a bulking agent 
of concentration 6% (w/w) was added to deionized water and mixed 
for 45 min. 1.5 ml of the various polymer solutions was pipette out 
into the cylinder cavities pre-oiled with mineral oil. The formulation 
was subjected to a freeze-phase in a freeze-dryer at-60°C for 2h & 
the dying phase was executed at a pressure of 25 m-tor for 24 h. 
Wafers were stored in glass jars with 2g of desiccant sachets [51]. 
Rolling method 
A solution or suspension containing drug is rolled on a carrier. The 
solvent is mainly water or a mixture of water and alcohol. The wafer 
is dried on the rollers and cut into desired shapes and sizes. Other 
ingredients including active agents dissolved in a small portion of 
aqueous solvent using the high-shear processor. Water soluble 




Fig. 4: Rolling method 
 
Evaluation of wafers [53, 54] 
A. Organoleptic Evaluation  
This is the most essential step in case of most oral formulation due 
to more residence time in the oral cavity. The product should 
possess the desired features of sweetness and flavour which is 
acceptable to a large mass of the population. Experiments using 
electronic tongue measurement have also been reported to 
distinguish between sweetness levels in taste masking formulation. 
In vitro methods of utilising taste sensors are being used for this 
purpose [55, 56]. 
B. Morphological studies 
The scanning electron microscopy (SEM) study refers the 
differences between upper and lower side of the films. It also helps 
in the determination of the distribution of API. Near-Infrared 
chemical imaging (NIR-CI) study helps in determining the difference 
between drug distributions in drug loaded films and 
recrystallization [57]. 
C. Mechanical properties 
Mechanical properties of wafers are evaluated using TA. XT2 texture 
analyser equipment equipped with a 5 kg load cell. Wafers are held 
between two clamps positioned between 3 cm. During 
measurements, the strips were pulled at a rate of 2 mm/s. The force 
and elongation were measured when wafer breaks [58].  
The following mechanical properties are measured:  
a. Thickness 
The thickness of the film can be measured by micrometre screw 
gauge at different strategic locations (at least 5 locations). This is 
essential to determine uniformity in the thickness of the film as this 
is directly related to the accuracy of dose in the film [59]. 
b. Dryness/Tack test 
Tack is the tenacity with which the wafer adheres to an accessory 
(a piece of paper) that has been pressed into contact with the 
wafer [60]. 
c. Tensile strength 
It is the maximum stress applied to the point at which the wafers 
sample breaks [61]. 
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d. Percent elongation 
When stress is applied, wafer sample stretches and this is referred to 
as strain [62]. 




e. Tear resistance 
The maximum stress or force that is generally found near the onset 
of tearing (2inch/mm) required to tear the film of 51 mm is 
recorded as tear resistance value in N or pound-force [63]. 
f. Folding endurance 
It is determined by repeated folding of the wafer at the same place 
till it breaks [64]. 
g. Young’s modulus 
It is the measure of the stiffness of wafers. Hard and brittle wafers 
demonstrate a high tensile strength and Young’s Modulus with small 
elongation. 




h. Stickiness determination 
It is evaluated by texture method usually for measurement of the 
tack of pressure sensitive adhesives. 
i. Swelling properties 
Wafer swelling study is conducted using stimulated saliva solution. The 
wafer sample is weighed and placed in a stainless steel wire mesh. The 
mesh containing wafer sample is submerged into 15 ml medium in a 
plastic container. Increase in the weight of the wafers determined at pre-
determined time interval until a constant weight is observed [65].  
Degree of swelling = (wt–wo)/wo 
Wt= weight of wafer at time t 
Wo= weight of wafer at time t 
j. Contact angle measurement 
Time-dependent contact angle is measured by an optical contact 
angle meter. The contact angle measured by different methods like 
the tangential method, width height ratio, circle fitting and sessile 
drop fitting [66]. 
k. Transparency 
The transparency of the wafers can be determined using a UV 
Spectrophotometer by cutting the wafers into rectangles and placing 
them on the internal side of the spectrophotometer cell. The 
transparency is determined at 600 nm [53, 54]. 
D. Taste evaluation 
Taste acceptance was measured by a taste panel consisting of human 
volunteers with 10 mg drug and subsequently wafer sample 
containing 10 mg drug held in the mouth until disintegration, then 
spat out time and bitterness level was determined [67]. 
E. Assay/Content uniformity 
This is determined by any standard assay method described for the 
particular API in any of standard pharmacopoeia. The limit of 
content uniformity is 85-115% 
F. Disintegration time 
The disintegration time limit of 30 sec or less for strips of 5-30g by 
disintegrating test apparatus can be applied. Although there are no 
specifications in pharmacopoeias [68]. 
G. In vitro dissolution and residence time 
Dissolution testing is performed by using standard basket/paddle 
apparatus. The medium will essentially be selected as per sink 
conditions and highest dose of API [69]. 
H. Stability testing 
A piece of wafer preparation was stored in an aluminium package at 
25 °C with 50-60% humidity (normal condition) and another wafer 
at 40 °C with 75% humidity (accelerated conditions), and both are 
observed [69]. 
I. In vivo evaluation 
An animal study can be conducted using Hamster Cheek Pouch 
Model, which is not performed now-a-days [70]. 
Established parameters of formulation variables 
A. Concentration of HPC 
Lower and upper limits were determined to be 1% (w/v) and 10% 
(w/v) respectively. The upper limit of 10% (w/v) was set because 
wafers of higher polymer concentration were difficult to remove 
from the mould. 
B. Concentration of diluent 
The concentration of diluent would affect both the solubility and 
textural properties of the matrices. Lower and upper limits are 1% 
(w/v) and 5% (w/v) respectively. 
C. Type of mould 
Polystyrene mould trays proved to be the most successful with 
minimum deformation of the final product as those moulds could be 
easily split down the middle to release the wafer. 
D. Type of lubricant 
Mineral oil produced the greatest ease of removal of the product as 
compared to the other lubricants analysed, impairing minimal 
hydrophobicity and having no effect on the taste of the final product 
as opposed to other substances such as maize oil. 
E. Freeze-drying parameters 
The melting and discoloration of the matrices occurs on storage. This 
is attributed to moisture present within the products, indicating that 
the freeze drying process needed to be conducted for a longer period. 
F. Gelation of matrices 
The characteristics for matrix formation require assessment of 
forms on the basis of selection of a suitable polymer. Gelation of 
polymer would delay the disintegration and ultimately release of 
active substances [71]. 
Packaging of oral wafers [72, 73] 
Selected characteristics of packaging materials:  
• They must protect the preparation from environmental conditions. 
• They must be FDA approved. 
• They must meet applicable tamper resistant requirements. 
• They must be non-toxic and must not be reactive with the product. 
• They must not impact to the products taste and odour.  
a. Single pouch 
It is used for quick dissolve soluble films with high barrier 
properties. The pouch is transparent. The foil lamination has 
essentially zero transmission of both gas and moisture. 
b. Blister card with multiple units 
The blister container consists of two components: the blister, which 
is formed cavity that holds the product and the lid stock which seals 
the blister. 
c. Polyvinyl chloride 
The most commonly used blister material is PVC. This material, 
which provides a nominal or zero barriers to moisture, is used when 
the product does not require effective moisture production. 
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d. Barrier film 
They provide moisture protection, materials such as polycholo-
triflurothylene and polypropylene is used. 
Future prospects, challenges and marketing status [74-75] 
The drug delivery sector of fast dissolve products has grown rapidly 
from sales in 2001 of about $850 million to 2005 were estimated 
sales were around $1.4 billion (IMS Data). The modification of this 
technology to provide a prolonged release mucoadhesive system 
seems promising. It is envisaged that this system will be appreciated 
to many drugs requiring the extended release of bioactive material. 
Therefore, the lyophilized wafer matrices developed in this study 
are highly effective in the rapid delivery of drugs, using the oral 
route as a site of administration. 
The market of these types of product is in excess of $15 billion 
worldwide. Currently, worldwide sales of drugs that incorporate a 
fast dissolve technology are more than 40%. The growth is fuelled 
by patient demand and industry estimated show that approximately 
88% of patients prefer taking medications that is incorporated in a 
fast dissolving dosage form as 40% of them faces difficulties in 
swallowing traditional tablets. 
CONCLUSION 
In the recent trend of obtaining more palatable dosage form, wafers 
as an orodispersible film have made its own place & met the 
expectation of the rising demand. Wafers are formulated as 
advancement to the oral fast dissolving films with its special 
properties of high absorption and high bioavailability. It is popular 
among people of all ages but particularly among the geriatric and 
paediatric population because of is compatibility and good mouth 
feel. The marketed products of wafers are still less, but there are 
many more to come in the recent years.  
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